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Abstract
The nucleotide-binding domain, leucine-rich repeat (NLR) proteins are a recently discovered
family of intracellular pathogen and danger signal sensors. NLRs have emerged as important
contributors to innate immunity in animals. The physiological impact of these genes is
increasingly evident, underscored by the genetic association of variant family members with an
array of inflammatory diseases. The association of mutations in NLR genes with
autoinflammatory diseases indicates an important function of these genes in inflammation in vivo.
This review summarizes the role of the inflammasome NLR proteins in innate immunity and
inflammatory diseases and explores the possible utility of some of these NLRs as pharmacological
targets.
The nucleotide-binding domain (NBD), leucine-rich repeat (LRR) (NLR) gene family is an
evolutionarily conserved family of genes, important for immune function in animals (1–3).
There are >20 NLR genes in humans. The NLR gene family members were discovered by
their structural similarity to the MHC class II gene master regulator CIITA and other NBD-
LRR-containing proteins (4). NLR genes encode cytoplasmic proteins with a tripartite
domain structure that is conserved with a subclass of plant disease resistance genes (3). The
tripartite structure of NLRs consists of a variable N-terminal effector domain, a central
NBD, and a variable number of C-terminal LRRs. Fig. 1 provides schematics of the domain
structures of the NLR proteins described in this review. The NLRs are responsible for rapid
sensing of pathogen-associated molecular patterns (PAMPs) such as the bacterial cell wall
components LPS, lipoproteins, and flagellin (5–11), bacterial and viral nucleic acids (12–
15), and the fungal cell wall components zymosan and mannan (16). In addition, NLRs also
sense damage-associated molecular patterns (DAMPs) such as ATP (17), uric acid (18, 19),
amyloid-β (20), asbestos (21, 22), silica (21), hyaluronan, and heparan sulfate (23).
However a major unresolved issue in the field is how an NLR acts as a sensor, because
direct evidence of NLR proteins binding to a specific pathogen- or non-pathogen derived
ligand is lacking. Regardless of the mechanism, the sensing of PAMPs and DAMPs by NLR
proteins can result in the assembly of a caspase-1 activating multiprotein complex referred
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to as the “inflammasome” (2). This is similar to the cytoplasmic multiprotein complexes
assembled for the activation of caspase-9 and caspase-8 referred to as the apoptosome
(containing Apaf-1) (24) and the death-inducing signaling complex (Fas/CD95-DISC) (25),
respectively. The protein components of the caspase-activating platforms are present as
inactive monomers that oligomerize on exposure to the activating PAMP or DAMP signal.
Inflammasome formation results in the cleavage of caspase-1 from its inactive proprotein
form to its active mature form. This active caspase-1 then processes the cleavage of pro-IL-1
β and pro-IL-18 into mature IL-1 β and IL-18, respectively. Although IL-1 β and IL-18 are
the most widely studied targets of caspase-1, two recent studies have identified >70 new
targets of caspase-1 ranging from chaperones, cytoskeletal and translation machinery, and
glycolysis and immune proteins (26, 27). There are several studies and related reviews
analyzing the role of the NLR gene family in infectious diseases, but this review focuses on
the role of the inflammasome NLRs in inflammatory diseases.
NLR gene family and NLR inflammasomes
The well known inflammasomes, the NLRP1, NLRP3, NLRC4, and NAIP5 inflammasome
complexes, and their key component proteins will be discussed in brief in this section. Fig. 2
depicts the triggering PAMPs and DAMPs and the key component proteins of the four
inflammasomes discussed below.
The NLRP3 inflammasome
The NLR family, pyrin domain-containing (NLRP) 3 (NLRP3; also called Cryopyrin,
NALP3, PYPAF1, CIAS1, and CLR1.1) inflammasome is activated by the presence of
pathogen products such as nucleic acids (12–15), LPS (12, 13, 18, 28), lipooligosaccharide
(29), and muramyldipeptide (MDP) (30); certain toxins such as nigericin (Streptomyces
hygroscopicus) and maitotoxin (marine dinoflagellates) (17); cellular danger signals such as
ATP (17), uric acid crystals (18), hyaluronan and heparan sulfate (31), and amyloid-β (20),
environmental danger signals such as asbestos and silica (21, 32); and alum and other
particulate adjuvants (32, 33). NLRP3 forms a multiprotein complex, referred to as the
NLRP3 inflammasome, with the adaptor protein apoptosis-associated speck-like protein
containing a caspase activating and recruitment domain (ASC) (28) and procaspase-1.
Association of NLRP3 with ASC is required for recruitment of procaspase-1 (34). The
caspase activating and recruitment domain (CARD) of ASC is used to recruit procaspase-1
by CARD-CARD interactions, thus leading to the processing of procaspase-1 into active
caspase-1 (35).
The NLRP1 inflammasome
The human NLRP1 (also called CARD7, DEFCAP, and CLR17.1) inflammasome was the
first caspase-1-activating inflammasome to be identified (36). There is only one Nlrp1 gene
in humans in contrast to three paralogues in mice; Nlrp1a, Nlrp1b, and Nlrp1c (37). The
NLRP1 protein in humans consists of an N-terminal pyrin domain central, an NBD, an
NBD-associated domain (NAD), LRR and function to find domains (FIIND), and a C-
terminal CARD domain. The mouse counterparts vary in structure from the human protein;
Nlrp1a lacks the N-terminal pyrin domain, Nlrp1b lacks both the pyrin and NAD domains,
and Nlrp1c lacks all but the NBD and LRR domains. Initial studies on NLRP1 using cell
extracts suggested that the NLRP1 inflammasome in humans consisted of NLRP1,
caspase-1, caspase-5 (not present in mice), and ASC (38, 39). Even though the presence of
ASC is not required for processing of caspase-1 by the NLRP1 inflammasome, it does
augment this function (40). The mouse Nlrp1b inflammasome is activated in response to
Bacillus anthracis (41) and specifically to the lethal toxin. Faustin et al. used a cell-free
system with recombinant NLRP1 inflammasome components to show inflammasome
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assembly and caspase-1 activation in response to the peptidoglycan component MDP (40).
Hsu et al. showed that MDP stimulation of macrophages leads to association of NLRP1 with
nucleotide oligomerization domain (NOD) 2 (41). Gel filtration experiments revealed a
complex consisting of NLRP1, NOD2, and caspase-1. Moreover, Bacillus anthracis
infection also induces NOD2- and caspase-1-dependent IL-1 β secretion. These results
suggest the existence of a NLRP1- and NOD2-containing inflammasome and the potential
for MDP to activate both NLRP1 and NOD2. However there is no data to show that MDP
binds to either NLRP1 or NOD2; thus, how MDP activates this pathway is unclear.
The NLRC4 inflammasome
NLR family, CARD-containing (NLRC) 4 (NLRC4; also called IPAF, NOD27, and
CLR16.1) is a cytosolic sensor of flagellin, flagellated pathogens such as Salmonella
typhimurium (6, 7, 34) and Legionella pneumophila (5), and nonflagellated pathogens such
as Shigella flexneri (9), and Pseudomonas aeruginosa (11). NLRC4 forms a homo-
oligomeric inflammasome with caspase-1 (34). Initial characterization of NLRC4 in human
tissues and cell lines demonstrated its direct association with the CARD domain of
procaspase-1 through CARD-CARD interactions (42, 43). This interaction can cause
autocatalytic processing of procaspase-1 into caspase-1 (43). A constitutively active NLRC4
could cause autocatalytic processing of procaspase-1 leading to caspase-1-dependent
apoptosis in transfected cells (43). In macrophages, caspase-1 activation and IL-1 β release
by cytoplasmic flagellin requires NLRC4 (6, 7, 34). NLRC4 can interact directly with
procaspase-1 through CARD-CARD interaction; however, direct interaction of ASC with
NLRC4 has not been demonstrated. Nonetheless, ASC-deficient macrophages show
defective caspase-1 activation and IL-1 β release in response to Salmonella, Shigella, and
Pseudomonas infection, indicating that the function of NLRC4 is ASC dependent (9, 11,
34).
The NAIP5 inflammasome
The NLR apoptosis-inhibitory protein (NAIP) 5 (also called BIRC1 and NLRB1) is also a
cytosolic sensor of flagellin. Although the human genome has one Naip5 gene, there are
seven paralogues of NAIP, Naip1-7, in mice (44). Based on coimmunoprecipitation studies
using overexpressed Myc-tagged NAIP and hemagglutinin-tagged NLRC4 in HEK293 cells,
these two proteins can coassociate, suggesting that they can be part of the same caspase-1-
activating inflammasome (45). Recently, Lightfield et al. reported a novel role for NAIP5 in
inflammasome activation in response to the C terminus of flagellin and L. pneumophila
infection (10). Interestingly, whereas transduction of macrophages with a C-terminal 35-aa
fragment of flagellin led to NAIP5-dependent cell death, full-length flagellin induced
NAIP5-independent but NLRC4-dependent cell death and IL-1β release, suggesting a
separation of duty for NAIP5 and NLRC4. Moreover, because NLRC4 can sense some
nonflagellated bacteria (9, 11), this might point to a mechanism for differential sensing of
bacteria via the regulation of inflammasome components. However, NAIP5 has no caspase
domain and needs NLRC4 to activate procaspase 1. Thus, NAIP5 appears to possess
NLRC4-dependent and -independent functions.
Inflammasome NLRs and inflammatory disease
NLR-related inflammatory diseases can be classified into three categories based on disease
resulting from the following: 1) mutation of core components of the inflammasome
complexes (intrinsic inflammasomopathies); 2) aberrant activation of the inflammasome
complex (acquired or complex inflammasomopathies); and 3) mutation of accessory or
regulatory proteins upstream or downstream of the inflammasome complex (extrinsic
inflammasomopathies) such as pyrin or the proline serine threonine phosphatase interaction
protein PSTPIP1 (46). The first two will be discussed in this review, but readers can refer to
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Autosomal dominant mutations in NLRP3 in humans leads to three autoinflammatory
syndromes collectively referred to as cryopyrin-associated periodic syndromes (CAPS; also
called cryopyrinopathies) (48–51). Gain-of-function mutations of NLRP3 cause a lowered
activation threshold that leads to IL-1 β secretion even in the absence of a stimulus in vitro
(36, 52, 53). All CAPS are characterized by increased levels of IL-1 β in the absence of
infection. CAPS consist of a spectrum of diseases ranging from the mild, such as familial
cold autoinflammatory syndrome (FCAS), to the intermediate, such as Muckle-Wells
syndrome (MWS), to the severe, such as chronic infantile neurological, cutaneous and
articular (CINCA) syndrome, also known as neonatal-onset multisystem inflammatory
disease (NOMID). All three syndromes present with fever, urticaria-like rash, and varying
degrees of arthropathy and neurological manifestations (4, 54–56). FCAS consists of the
mildest symptoms, including cold-induced urticaria and mild arthralgia. MWS is
characterized by spontaneous urticaria (not cold-induced), sensorineural hearing loss,
arthralgia, and in some cases renal amyloidosis. CINCA is the most severe, with
spontaneous urticaria, deforming arthropathy, sensorineural hearing loss, and chronic aseptic
meningitis.
Hoffman et al. sequenced a region within chromosome 1q44 that was previously known to
contain mutations that lead to FCAS and MWS (57). This screening approach led to the
discovery of four distinct mutations in exon 3 of a nine-exon gene that segregated with the
disorder in three families with FCAS and one family with MWS. This gene is now referred
to as NLRP3. NLRP3 is a cytoplasmic protein that is expressed in monocytes, macrophages,
granulocytes, dendritic cells, nonkeratinized epithelial cells, osteoblasts, and uroepithelial
cells (58, 59). NLRP3 is composed of three distinct domains: an N-terminal pyrin domain, a
central NBD, and C-terminal LRRs. All 84 of the disease-associated mutations lie within
exon 3, which encodes the central NBD of NLRP3 (60). The pyrin domain of NLRP3 is
essential for homotypic interactions with the pyrin domain of other proteins. The NBD is
thought to be involved in the oligomerization of NLRP3 to form the inflammasome
complex. The LRR domain is suggested to mediate interaction with intracellular or
extracellular PAMPs or DAMPs, albeit no evidence has been reported. Additional studies
reported the role of NLRP3 in response to bacterial RNA, dsRNA, viral RNA, uric acid
crystals, TLR ligands, bleomycin, and ATP using Nlrp3-deficient mice (12, 13, 18, 28).
Recently, the Strober and Hoffman laboratories separately generated mice expressing
mutations corresponding to human FCAS or MWS mutations (61, 62). Meng et al. generated
a mouse expressing the R258W mutation corresponding to the human R260W substitution
(62). Brydges et al. generated two lines of mice carrying the A350V and L351P mutations
that correspond to the human A352V and L353P mutations downstream of a LoxP – flanked
neomycin resistance cassette in reverse orientation (61). When these mice were crossed with
Cre recombinase-expressing mice they would express the mutated NLRP3 protein in all
tissues (CreZ), in myeloid cells only (CreL), or after exposure to tamoxifen (CreT). The
mice generated by both studies developed severe cutaneous lesions associated with
inflammatory cell infiltrates, recapitulating some of the urticaria-like skin lesions in MWS
patients. Interestingly, both studies could recapitulate human disease by either expressing
mutant NLRP3 only in myeloid cells (61) or by the generation of bone marrow chimeras
with the mutant R258W protein in bone marrow cells (62).
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This is an autoimmune disease resulting from destruction of melanocytes causing patches of
depigmented skin in patients. Vitiligo patients are at a higher risk for the development of
other autoimmune diseases such as rheumatoid arthritis, diabetes, lupus, and thyroid disease.
Fine scale association analyses of patients with vitiligo identified Nlrp1 variants that are
associated with the development of vitiligo alone (63). The mechanism by which NLRP1
leads to skin hypopigmentation in vitiligo remains unknown.
Complex or acquired inflammasomopathies
Gout/pseudogout
Gout and pseudogout are rheumatic diseases caused by deposition of monosodium urate
(MSU) and calcium pyrophosphate dihydrate crystals respectively, in joints and periarticular
tissues. This deposition can lead to acute or chronic inflammation of the joints. MSU and
calcium pyrophosphate dihydrate crystals increase caspase-1 activation and IL-1 β release
from murine macrophages in an NLRP3- and ASC-dependent manner (18). The importance
of IL-1 β in gout studied in mice was further supported by the resistance of mice deficient in
the IL-1 and TLR signaling adaptor protein MyD88 to MSU-induced inflammation (64).
Although TLR deficient mice still showed inflammation, the IL-1 β receptor deficient mice
did not, thus indicating a specific role for IL-1 signaling in the pathology. Bone marrow
reconstitution experiments established that IL-1R expression in nonhematopoietic and
hematopoietic cells is required for the initiation of inflammation upon MSU stimulation,
indicating IL-1 β engagement to its receptor in this model.
Asbestosis and silicosis
Prolonged inhalation of asbestos and silica leads to two environmentally induced forms of
pulmonary fibrosis referred to as asbestosis and silicosis, respectively. Alveolar
macrophages from individuals with prolonged exposure to asbestos exhibit enhanced IL-1 β
release (22). Moreover, Nlrp3- deficient mice show decreased IL-1 β release in response to
asbestos and silica (21, 32), indicating a role for NLRP3 in the immune response to asbestos
and silica. Silica crystals, once phagocytosed, can cause lysosomal damage leading to
release of the lysosomal protease, cathepsin B, which can activate the NLRP3
inflammasome. Inhibition of phagosomal acidification or cathepsin B impairs NLRP3
inflammasome activation (32). In the bleomycin-induced lung injury model of fibrosis, the
NLRP3 inflammasome is triggered by local uric acid release in response to DNA damage
and degradation after bleomycin injury, suggesting that uric acid may be one of the
triggering DAMPs in lung fibrosis and disease (65).
Guadeloupe variant periodic fever syndrome (FCAS2)
This syndrome was first reported in two families in Guadeloupe and thus named the
Guadeloupe variant periodic fever syndrome (66). Based on the similarities in symptoms to
FCAS, this syndrome is also referred to as FCAS2. Individuals with this syndrome present
with cold-induced heterogeneous symptoms including fever, arthralgia, myalgia,
sensorineural hearing loss, aphthous ulcers, and lymphadenopathy.
Genetic studies in patients with the Guadeloupe variant periodic fever syndrome revealed
two missense mutations, one nonsense mutation, and one deletion mutation in the Nlrp12
gene. The nonsense mutation caused a truncation within the NBD of the protein whereas the
splice mutation caused a deletion of the C-terminal LRRs. NLRP12 was recognized as one
of the few NLR proteins that can suppress NF-κB signaling (67, 68). Both of the missense
mutations in Nlrp12 caused a reduction in the suppression of NF-κB signaling by NLRP12,
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whereas the NBD mutation caused a more significant impact on normal NLRP12-induced
NF-κB signaling as compared with the LRR mutation.
NLRs as potential pharmacological targets
Activation of the various inflammasome complexes discussed in this review leads to
activation of caspase-1 and production of the proinflammatory cytokines IL-1 β and IL-18.
Although specific drugs that interfere with inflammasome components are under
development, there have been several clinical studies exploring the modification of the IL-1
β pathway owing to its central role in several diseases (69). Modulation of IL-1 β function
has been approached at three levels: firstly, the release of IL-1 β can be blocked by the
inhibition of upstream pathways (70, 71); secondly, the released cytokine can be neutralized
or its receptor blocked to prevent downstream signaling (70, 72); and finally, the signaling
mechanisms in the target cells can be blocked by disrupting further downstream signaling
pathways (73–78). A detailed list of the available drugs targeting the above mentioned steps
of regulation for the IL-1 β pathway along with their mechanisms of action is provided in
Table II. There are some caveats in the use of some of the inhibitors because they can inhibit
not only the IL-1 β but also the IL-18 pathways. A better understanding of the underlying
mechanism for each disease would provide more accurate targets. Target specificity would
enable a more accurate control of pathology. CAPS symptoms remain the gold standard, as
they can be reversed by treatments with the IL-1R antagonist Kineret. Although some of
these drugs are efficacious in relieving symptoms (72, 74–78), several others are in clinical
trials or remain to be tested in humans, awaiting further studies of their mode of action (70,
71).
Conclusions
The association of the NLRs with several immunological diseases suggests a role for these
proteins in both innate and adaptive immunity. Recent studies are beginning to unfold the
role of this family in immune regulation and dysregulation; however, a plethora of questions
remain unanswered. Firstly, how is the diversity of PAMPs and DAMPs sensed and
differentiated from self-molecules? Secondly, how does such a wide range of symptoms in
CAPS arise from mutations that are relatively clustered in the NBD of NLRP3? Thirdly, is
there a cross-talk between the different inflammasome pathways and do they compensate for
each other? Finally, what are the DAMPs and PAMPs that might activate the inflammasome
pathways in complex immune diseases such as type II diabetes, multiple sclerosis, and
atherosclerosis? Considering the vibrant research in this field, significant progress is likely
to resolve several of these issues.
Abbreviations used in this paper
NBD nucleotide-binding domain
ASC apoptosis associated speck-like protein containing a caspase recruitment
domain
CAPS cryopyrin associated periodic syndrome
CARD caspase activating and recruitment domain
CINCA chronic infantile neurological, cutaneous and articular syndrome
DAMP damage-associated molecular pattern
FCAS familial code autoinflammatory syndrome
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NAIP NLR apoptosis inhibitory protein
NLR nucleotide-binding domain, leucine-rich repeat
NLRC NLR family, CARD containing (inflammasome)
NLRP NLR family, pyrin domain-containing (inflammasome)
NOD nucleotide oligomerization domain
NOMID neonatal onset multisystem inflammatory disease
PAMP pathogen-associate molecular pattern
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Domain organization of inflammasome NLRs. NLR proteins have a conserved tripartite
structure consisting of an N-terminal effector domain, a central NBD, and a variable number
of C-terminal LRRs. Abbreviations not defined elsewhere: BIR, baculovirus inhibitor of
apoptosis repeat; FIIND, function to find domain; PYR, pyrin domain.
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NLR Inflammasomes. In response to PAMPs or DAMPs, the NLRs are activated to form
multiprotein caspase-activating platforms referred to as inflammasomes. The NLRP1
inflammasome when activated by MDP or anthrax lethal toxin can recruit procaspase-1 via
direct CARD-CARD interactions and cause its autocatalytic cleavage to mature caspase-1.
The activated caspase-1 can then process IL-1 β and IL-18 from their inactive proproteins to
mature active forms. The NLRP3 inflammasome is activated in response to several PAMPs
and DAMPs, including but not restricted to nucleic acids (12–15), LPS (13),
lipooligosaccharide (29),MDP(30), ATP(17), uric acid crystals (18), hyaluronan and heparan
sulfate (31), amyloid- β (20), and asbestos and silica (21, 32). NLRP3forms a multiprotein
inflammasome complex with the adaptor protein ASC and procaspase-1. Association of
NLRP3 with ASC is required for recruitment of procaspase-1. The CARD domain of ASC is
used to recruit procaspase-1 by CARD-CARD interactions, thus leading to the processing of
procaspase-1 into active caspase-1. Caspase-1 is in turn critical for the processing and
release of IL-1 β and IL-18. The NLRC4 inflammasome is a cytosolic sensor of flagellin
and pathogens such as S. typhimurium, S. flexneri, and L. pneumophila (5–9, 11, 34).
NLRC4 forms a homo-oligomeric inflammasome with caspase-1. The C-terminal, 35-aa
fragment of flagellin is sensed by NAIP5 leading to a NAIP5-dependent cell death whereas
full-length flagellin induces NAIP5-independent but NLRC4-dependent cell death and IL-1
β release (10). BIR, baculovirus inhibitor of apoptosis repeat; FIIND, function to find
domain; PYR, pyrin domain.
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Table I
Disease-associated mutations
NLR Mutation(s) (Amino acid change) Disease Association Ref.
NLRP3 A439V, V198M, E627G, A352V FCAS and MWS 57
R260W, D303N, T348M, A439T, and G569R FCAS and MWS 54
F575S, Q306L, T436N, H358R, M662T, D303N, F309S CINCA 58
L264H, D303N, A374N, Y570C, F523L CINCA 55
L353P FCAS 56
T348M, E354D, L632N, R260L, R260P, D303N, D303G, F309S, T405P,
T436I, Y570C
CINCA 51
NLRP1 L155H Vitiligo 63
NLRP12 R284X, V635T Guadeloupe variant periodic fever
syndrome
66













Jha and Ting Page 15
Table II
Pharmacological inhibitors
Action Target Drug (Company) Description Ref.
Suppression of IL-1β production
Caspase-1 inhibition Caspase-1 Pranalcasan (Aventis/Vertex) VX-740; VX-765 70
IL-1 β posttranslational processing Unknown CP424174, CP412245 (Pfizer) Diarylsulphonyl urea 70
IL-1 β production inhibitor Unknown CJ14877, CJ14897 (Pfizer) Pyridine-2-carboxylates 70
Unknown LL-Z1217a (Pfizer) Terpenoid lactone 70
Suppression of IL-1 β release
IL-1 β release inhibitors Unknown CP424174 (Pfizer) Diarylsulphonyl urea 70
Neutralization of secreted IL-1 β IL-1 Anakinra (Kineret, Amgen)
rhuIL-1Ra
a 70
IL-1 IL-1trap (Regeneron/Novartis) Human IL-1R1:IgG1 protein 70
IL-1 CDP-484 (Celltech) PEGylated Ab 70
Inhibition of IL-1R signal
transduction











May also inhibit IL-18R and TLR signal transduction.
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